ERN1 and diffuse large B-cell lymphoma: Some of the drug targets such as PI3K/Akt are known to interact with IRE1α signaling; thus, it is worth investigating whether the combination of inhibitors of these pathways would potentiate the antiproliferative and pro-apoptotic effect in DLBCL cells.